Teladoc Health (NYSE:TDOC) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Teladoc Health (NYSE:TDOC) posted its quarterly earnings results on Wednesday. The health services provider reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05, FiscalAI reports. The business had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. Teladoc Health updated its Q1 2026 guidance to -0.450–0.350 EPS and its FY 2026 guidance to -1.100–0.700 EPS.

Teladoc Health Stock Performance

Shares of NYSE:TDOC traded up $0.12 during trading on Wednesday, hitting $4.66. 6,087,236 shares of the stock were exchanged, compared to its average volume of 6,532,484. The company has a market capitalization of $826.12 million, a price-to-earnings ratio of -3.64 and a beta of 2.12. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $11.55. The company’s fifty day simple moving average is $6.11 and its 200-day simple moving average is $7.24.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TDOC shares. Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Evercore reduced their price target on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a research report on Thursday, October 30th. Barclays started coverage on Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective on the stock. Citigroup lowered their target price on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.12.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of Teladoc Health stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the sale, the chief executive officer owned 201,036 shares in the company, valued at $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Fernando M. Rodrigues sold 4,209 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total transaction of $31,483.32. The SEC filing for this sale provides additional information. Insiders sold 33,288 shares of company stock valued at $251,684 in the last ninety days. 0.58% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teladoc Health

A number of hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in Teladoc Health by 23.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Teladoc Health in the 4th quarter worth approximately $9,156,000. Bridgeway Capital Management LLC acquired a new position in shares of Teladoc Health in the 2nd quarter worth approximately $8,729,000. Man Group plc increased its holdings in Teladoc Health by 113.8% during the 4th quarter. Man Group plc now owns 1,620,633 shares of the health services provider’s stock valued at $11,344,000 after purchasing an additional 862,454 shares in the last quarter. Finally, Nuveen LLC increased its holdings in Teladoc Health by 38.7% during the 4th quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after purchasing an additional 742,240 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.